

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04426825 ML41256

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, single-arm, phase II, multicenter study designed to evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04426825 ML41256
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
